<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01528007</url>
  </required_header>
  <id_info>
    <org_study_id>03062010</org_study_id>
    <secondary_id>2010-021123-26</secondary_id>
    <nct_id>NCT01528007</nct_id>
  </id_info>
  <brief_title>Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention</brief_title>
  <official_title>Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention - a Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute for Health and Welfare, Finland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute for Health and Welfare, Finland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this research is to explore the efficacy of the opiate antagonist, naltrexone as
      combined with CBT-intervention in the treatment of pathological gambling (PG). The study
      period is 2011-2014 during which one hundred Pathological Gamblers will be recruited to
      participate to this placebo-controlled double-blind trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All participants have to be able to read and understand the patient information sheet and
      sign the informed consent. All participants are free to stop being in the study whenever they
      wanted. The patients are not paid or reimbursed for participation.

      The study periods is 21 weeks during which the participant's have 8 appointments with the
      researchers. During the meetings research data will be collected and the participant is
      having Controlled Behavioral Therapy (CBT) consulting from a trained therapist. At the study
      visits, the subjects are given written instructions for the proper use of naltrexone and
      advised to take 50 mg naltrexone approximately one hour before gambling or feeling urges to
      gamble (and to refrain from taking naltrexone at other times). In this study the maximal
      daily dose is 50mg of naltrexone. The medication is free for the subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PG-YBOCS.</measure>
    <time_frame>Up to 21 weeks.</time_frame>
    <description>The investigators will interview PG-YBOCS questionnaire from the participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alcohol use.</measure>
    <time_frame>Up to 21 weeks.</time_frame>
    <description>The investigators will ask the participants to fill in AUDIT questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life.</measure>
    <time_frame>Up to 21 weeks.</time_frame>
    <description>The investigators will ask the participants to fill in RAND 36 questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Pathological Gambling</condition>
  <arm_group>
    <arm_group_label>Placebo pill.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>50mg Naltrexone when needed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone pharmacotherapy</intervention_name>
    <description>Naltrexone 50mg when graving to gamble.</description>
    <arm_group_label>50mg Naltrexone when needed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pill with no active ingredients.</description>
    <arm_group_label>Placebo pill.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pathological gambling (scores 5+ from SOGS-R and DSM-IV criteria)

        Exclusion Criteria:

          -  acute hepatitis

          -  severe liver or kidney dysfunction

          -  suicide risk or severe depression or other untreated mental health problem

          -  participation to other gambling research at the same time

          -  the use of drugs (especially opiates)

          -  pregnancy

          -  prisoners

          -  retarded and mentally ill patients were also excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hannu Alho, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute for Health and Welfare, Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tuuli Lahti, Adjunct Professor</last_name>
    <role>Study Director</role>
    <affiliation>National Institute for Health and Welfare, Finland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute for Health and Welfare</name>
      <address>
        <city>Helsinki</city>
        <state>Uusimaa</state>
        <zip>00530</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2011</study_first_submitted>
  <study_first_submitted_qc>February 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2012</study_first_posted>
  <last_update_submitted>December 4, 2013</last_update_submitted>
  <last_update_submitted_qc>December 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute for Health and Welfare, Finland</investigator_affiliation>
    <investigator_full_name>Hannu Alho</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Pathological gambling</keyword>
  <keyword>Treatment intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gambling</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

